CLINICAL TRIALS PROFILE FOR MOEXIPRIL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for moexipril hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00588302 ↗ | Moexipril for Primary Biliary Cirrhosis | Completed | UCB Pharma | Phase 2 | 2003-06-01 | The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). |
| NCT00588302 ↗ | Moexipril for Primary Biliary Cirrhosis | Completed | Mayo Clinic | Phase 2 | 2003-06-01 | The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). |
| NCT00834067 ↗ | Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2003-10-01 | The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions. |
| NCT00835042 ↗ | Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2003-10-01 | The objective of this study is to compare the relative bioavailability of Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult non-smoking subjects under fasting conditions. |
| NCT00990301 ↗ | A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions | Completed | Paddock Laboratories, Inc. | Phase 1 | 1969-12-31 | The purpose of this study was to evaluate the relative bioavailability of Paddock Laboratories, Inc.'s test formulation of Moexipril/ Hydrochlorothiazide 15mg/25mg tablets with a reference formulation Uniretic®(Moexipril/ Hydrochlorothiazide) 15mg/25mg tablets, under fasting conditions. |
| NCT00992862 ↗ | A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions | Completed | Paddock Laboratories, Inc. | Phase 1 | 1969-12-31 | The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions. |
| NCT01669434 ↗ | Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery | Completed | University of Nebraska | Phase 4 | 2015-06-01 | Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for moexipril hydrochloride
Condition Name
Clinical Trial Locations for moexipril hydrochloride
Trials by Country
Clinical Trial Progress for moexipril hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for moexipril hydrochloride
Sponsor Name
